See more : Fab-Form Industries Ltd. (FBF.V) Income Statement Analysis – Financial Results
Complete financial analysis of Forte Biosciences, Inc. (FBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Forte Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Public Storage (PSA-PJ) Income Statement Analysis – Financial Results
- CountPlus Limited (CUP.AX) Income Statement Analysis – Financial Results
- Grand Hall Enterprise Co., Ltd. (8941.TWO) Income Statement Analysis – Financial Results
- Ardentec Corporation (3264.TWO) Income Statement Analysis – Financial Results
- Asian American Medical Group Limited (AJJ.AX) Income Statement Analysis – Financial Results
Forte Biosciences, Inc. (FBRX)
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.04M | 41.00K | 49.00K | 51.00K |
| Cost of Revenue | 9.00K | 0.00 | 36.00K | 54.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | -36.00K | -54.00K | -11.00K | 18.04M | 41.00K | 49.00K | 51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.86M | 5.59M | 13.85M | 10.00M | 2.68M | 50.46M | 29.11M | 27.22M | 19.17M |
| General & Administrative | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 265.68K | 8.56M | 4.52M | 3.83M |
| Selling & Marketing | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 12.54M | -292.00K | -255.00K | -232.00K |
| SG&A | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 12.81M | 8.27M | 4.27M | 3.60M |
| Other Expenses | -1.00 | 17.00K | -222.00K | -205.00K | -6.85K | 0.00 | 0.00 | -50.00K | 0.00 |
| Operating Expenses | 32.48M | 13.90M | 21.49M | 14.23M | 4.06M | 63.26M | 37.38M | 31.49M | 22.77M |
| Cost & Expenses | 32.49M | 13.90M | 21.49M | 14.23M | 4.06M | 63.89M | 37.67M | 31.74M | 23.01M |
| Interest Income | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 595.00K | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 173.38K | 1.93M | -1.84M | -102.00K | |
| Depreciation & Amortization | 9.00K | 36.00K | 36.00K | 54.00K | 11.00K | 625.00K | 292.00K | 255.00K | 232.00K |
| EBITDA | -32.48M | -13.90M | -21.45M | -46.43M | -4.05M | -43.69M | -36.71M | -31.17M | -22.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -250.77% | -91,065.85% | -64,155.10% | -44,552.94% |
| Operating Income | -32.49M | -13.90M | -21.49M | 17.83M | -4.06M | -45.85M | -37.63M | -31.69M | -22.95M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -254.23% | -91,778.05% | -64,675.51% | -45,007.84% |
| Total Other Income/Expenses | 1.01M | 17.00K | -222.00K | -205.00K | -5.00K | -1.40M | -1.30M | -1.79M | -102.00K |
| Income Before Tax | -31.48M | -13.88M | -21.71M | -46.49M | -4.07M | -47.26M | -38.93M | -33.48M | -23.06M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -262.01% | -94,948.78% | -68,322.45% | -45,207.84% |
| Income Tax Expense | 0.00 | -17.00K | -200.56K | 32.06M | -2.52K | 1.70M | -2.60M | -3.67M | -204.00K |
| Net Income | -31.48M | -13.86M | -21.71M | -78.54M | -4.07M | -48.96M | -38.93M | -33.48M | -23.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -271.43% | -94,948.78% | -68,322.45% | -45,207.84% |
| EPS | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| EPS Diluted | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| Weighted Avg Shares Out | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
| Weighted Avg Shares Out (Dil) | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors. Mr. Gryska was previously the Chief Financial Officer and Executive Vice President at Incyte. Prior to joining...
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice,...
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
DALLAS--( BUSINESS WIRE )--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
DALLAS--( BUSINESS WIRE )--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update.
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. “Forte is making excellent progress with its lead program FB-102, which is a direct result...
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (together with its affiliates, "Camac" or “we”), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today expressed concerns regarding the Company’s sizable trading price discount relative...
Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (together with its affiliates, "Camac" or “we”), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today expressed concerns regarding the Company's sizable trading price discount relative...
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provided a business update. “Forte is excited to continue down our new path as we develop novel compounds for...
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provided a business update. “Forte is excited to continue down our new path as we develop novel compounds for...
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation...
Source: https://incomestatements.info
Category: Stock Reports